GD2/PSMA Bi-specific CAR-T Cell Therapy

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT05437315
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
1 Year - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • bi-4SCAR GD2/PSMA T cells — BIOLOGICAL
    Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA positive tumor. Another goal of the study is to learn more about the function of the anti-GD2/PSMA bi-specific CAR-T cells and their persistency in patients.

Key Dates

First listed
Jun 29, 2022
Start date
Dec 31, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: bi-4SCAR-GD2/PSMA T Cell Therapy for GD2 and PSMA positive tumor

Primary Outcome Measure

Number of patients with adverse events. [ Time Frame: 6 months ]

Central Contacts

Related Studies